Related Experiment Video
Updated: Sep 18, 2025
12:40
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
15.0K
Rho kinase inhibitors: a patent review (2017-2023).
Daniela Rodrigues de Oliveira1,2, Heber Victor Tolomeu1, Carlos Alberto Manssour Fraga1,2
1Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio), Instituto de Ciências Biomédicas (ICB), Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil.
Expert Opinion on Therapeutic Patents
|June 24, 2025
Summary
Recent patents reveal novel Rho-associated protein kinase (ROCK) inhibitors and new therapeutic uses. This review explores advancements in ROCK-targeting drugs, building on recent FDA approvals.
Area of Science:
- Biochemistry and Pharmacology
- Drug Discovery and Development
Background:
- Rho-associated protein kinases (ROCK) are critical regulators of cellular processes.
- ROCK inhibitors represent a significant therapeutic target, underscored by recent FDA approvals.
Purpose of the Study:
- To review recent patent literature (2017-2023) on Rho-associated protein kinase (ROCK) inhibitors.
- To highlight novel ROCK inhibitors, advancements in existing compounds, and emerging therapeutic applications.
Main Methods:
- Comprehensive literature search of patent databases.
- Analysis of scientific publications related to ROCK inhibitors.
Main Results:
- Identification of novel ROCK inhibitors and their mechanisms of action.
- Progress assessment of previously investigated ROCK-targeting compounds.
- Exploration of new therapeutic avenues for ROCK inhibition.
Conclusions:
- The field of ROCK inhibitors is rapidly advancing, with significant patent activity.
- Approved ROCK inhibitors like fasudil, ripasudil, netarsudil, and belumosudil show therapeutic promise.
- Continued research and development hold potential for further clinical applications of ROCK inhibitors.
Related Concept Videos
01:24Small GTPases - Ras and Rho
4.3K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
4.3K
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
263
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
263
02:34Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
01:22PI3K/mTOR/AKT Signaling Pathway
4.0K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
4.0K
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
03:03mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K